Genome Editing– tag –
-
Editas Medicine Unveils Positive Preclinical Data for Gene Editing Candidate EDIT-401, Demonstrating Significant Reduction in LDL, Lp(a), and ApoB in Non-Human Primates
Investing.com USA Overview Editas Medicine announced positive preclinical data for its gene editing therapeutic candidate EDIT-401, showing significant reductions in LDL cholesterol, lipoprotein(a) (Lp(a)), and apolipoprotein B (ApoB) in... -
Intellia’s Lonvo-z Achieves 87% Reduction in HAE Attack Rate and 62% Attack-Free Patients in Pivotal Phase 3 In Vivo CRISPR Trial
GlobeNewswire USA Overview Intellia Therapeutics has reported highly positive Phase 3 HAELO clinical trial results for lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR gene editing therapy for hereditary angioedema (HAE). The therapy a... -
Non-Viral CRISPR/Cas9 HDR Platform Enables Stable Genetic Engineering of Solid Tumor Models, Overcoming Viral Vector Challenges
bioRxiv (Preprint) USA Overview This preprint reports research on a non-viral CRISPR/Cas9 Homology-Directed Repair (HDR) platform for stable genetic engineering of solid tumor models. This approach enables precise genome modification and... -
REPROCELL Develops Hypoimmune iPSC Engineering with AI-Designed CRISPR for Off-the-Shelf Cell Therapies
REPROCELL Japan Overview REPROCELL announced a method to develop hypoimmune iPSCs using AI-designed CRISPR, leveraging its StemEdit gene-editing platform. This approach targets key immune recognition genes like B2M and CIITA to create un... -
FUJIFILM Cellular Dynamics Opens New iPSC Manufacturing Facility and Reorganizes Life Sciences Leadership to Accelerate Cell Therapy and iPSC Business Expansion
FUJIFILM Cellular Dynamics / Indian Pharma Post Japan Overview FUJIFILM Cellular Dynamics announced the opening of its new headquarters and iPSC development and manufacturing facility in Madison, tripling its iPSC-based research product ... -
FDA Issues Draft Guidance to Streamline Regulatory Submissions for Cell and Gene Therapy Products by Leveraging Prior Knowledge
Pharmuni USA Overview The U.S. FDA has released new draft guidance aimed at accelerating the development of cell and gene therapy products for rare diseases. This guidance permits developers to leverage existing scientific, manufacturing... -
Intellia Therapeutics’ Lonvo-z Anticipates Key Phase 3 HAE Data Presentation at EAACI 2026
Simply Wall St USA Overview Intellia Therapeutics highlighted that additional data from the Phase 3 HAELO trial of lonvo-z (lonvoguran ziclumeran), its CRISPR-based therapy for hereditary angioedema (HAE), will be presented at the Europe... -
Beam Therapeutics’ Gene-Editing Candidate BEAM-302 Shows Positive Clinical Data in AATD Treatment, Hinting at Accelerated FDA Pathway
Simply Wall St USA Overview Beam Therapeutics reported positive clinical trial data for its gene-editing candidate, BEAM-302, demonstrating sustained protective protein levels in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). Th... -
Caribou Biosciences’ Off-the-Shelf Allogeneic CAR T Vispa-cel Shows Superior PFS to Approved Autologous CAR T Therapies in Lymphoma Phase 1
Fierce Biotech USA Overview Caribou Biosciences announced promising median progression-free survival (PFS) data from its Phase 1 clinical trial of vispacabtagene regedleucel (vispa-cel), an off-the-shelf allogeneic CAR T-cell therapy for... -
Sana Biotechnology to Announce Q1 Financial Results and Hypoimmune Cell Therapy Pipeline Progress at June Investor Conferences
Stock Titan USA Overview Sana Biotechnology is scheduled to present its Q1 2026 financial results and recent business updates on its hypoimmune cell therapy and in vivo gene editing platforms at multiple investor conferences in June 2026...
